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Abstract
Background: Severity of illness is an important consideration in making the decision to transfuse as it is the sicker
patient that often needs a red cell transfusion. Red blood cell (RBC) transfusions could potentially have direct effects
and interact with presenting illness by contributing to pathologies such as multi-organ dysfunction and acute lung
injury thus exerting a considerable impact on overall morbidity and mortality. In this study, we examine if
transfusion is an independent predictor of mortality, or if outcomes are merely a result of the initial severity
as predicted by Pediatric Risk of Mortality (PRISM) III, Pediatric Index of Mortality (PIM2), and day 1 Pediatric
Logistic Organ Dysfunction (PELOD) scores.
Methods: A single center retrospective study was conducted using data from a prospectively maintained transfusion
database and center-specific data at our pediatric ICU between January 2009 and December 2012. Multivariate
regression was used to control for the effects of clinical findings, therapy, and severity scores, with mortality as
the dependent variable. Likelihood ratios and area under the curve were used to test the fidelity of severity
scores by comparing transfused vs. non-transfused patients.
Results: There were 4975 admissions that met entry criteria. In multivariate analysis, PRISM III scores and serum
hemoglobin were significant predictors of transfusion (p < 0.05). Transfused and non-transfused subjects were
distinctly disparate, so multivariate regression was used to control for differences. Severity scores, age, volume
transfused, and vasoactive agents were significantly associated with mortality whereas hemoglobin was not. A
substantial number of transfusions (45 %) occurred in the first 24 h, and patients transfused later (24–48 h) were
more likely to die compared to this earlier time point. Likelihood ratio testing revealed statistically significant
differences in severity scoring systems to predict mortality in transfused vs. non-transfused patients.
Conclusions: This study suggests that RBC transfusion is an important risk factor that is statistically independent
of severity. The timing of transfusions that related strongest to mortality remained outside the purview of severity
scoring, as these happened beyond the timing of data collection for most scoring systems.
Keywords: Pediatric critical care, Transfusion, Acuity scores, Mortality prediction, PRISM, PELOD, PIM2, Pediatric
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Background
Transfusions are a necessary part of clinical practice,
though they have very specific deleterious effects (e.g.,
anaphylaxis, transfusion related acute lung injury, transfu-
sion associated circulatory overload) [1–3]. In addition,
transfusions have poorly characterized but multi-systemic
effects that are thrombogenic, immunosuppressive, and
inflammatory in nature leading to deterioration independ-
ent of presenting illness [4–8]. Thus, red blood cell (RBC)
transfusions could have direct and indirect effects by
interacting with the presenting illness, leading to a signifi-
cant impact on ICU morbidity and mortality [9–13].
The above pathophysiologic factors may explain why
restrictive transfusion protocols have been shown to re-
duce transfusions without any negative impact on out-
comes. Multiple prospective observational studies have
examined the impact of RBC transfusions in critically ill
patients [14, 15]. These studies have sought to establish
the safety of lower hemoglobin thresholds rather than
examine any specific negative impact or interactions of
transfusion with critical illness. Lower hemoglobin
thresholds have been established as safe by both adult
and pediatric studies [14–16]. As thresholds drop, the
patient’s clinical condition becomes more of a factor in
making the decision to transfuse. Controlling for the
confounding effects of the disease processes leading to
transfusion in the ICU setting is difficult since healthy
children require neither intensive care nor transfusion.
We hypothesize that transfusion has effects that associ-
ate with mortality that are independent from severity of
illness.
Therefore, we investigated whether transfusion status
had any residual impact on length of stay (LOS) or mor-
tality after controlling for well-established illness severity
scores (Pediatric Risk of Mortality (PRISM) III, Pediatric
Index of Mortality (PIM2), and Pediatric Logistic Organ
Dysfunction (PELOD)), in addition to other variables.
Severity scores provide us with predicted mortality as
they were developed to enable comparative analysis of
outcomes and benchmarking of care between different
ICUs [17, 18]. These scores are derivatives of multiple
physiological indices, laboratory values, and patient char-
acteristics. If transfusion continues to have a significant
association with outcomes after controlling for severity
scores, this would suggest at a minimum that transfu-
sion status captures aspects of acuity and risk not fully
addressed by these scores.
Methods
All pediatric patients (<18 years of age) admitted to our
tertiary care pediatric intensive care unit (PICU) be-
tween January 2009 and December 2012 were included
in the initial review. Data sources for the study included
electronic medical records (CERNER; Kansas City, MO),
Virtual PICU Systems, LLC database, and an Institu-
tional Review Board (IRB)-approved prospective transfu-
sion database. A wide range of clinical data are
systematically captured in this database including diag-
nosis, transfusion trigger, pre-transfusion hemoglobin,
timing of transfusion, volume and number of transfu-
sions, and clinical course. IRB approval for this study
was obtained prior to data collection. Further, none of
the authors had any competing interests to declare.
There were two groups of patients for this study, the
non-transfused group and the transfused group. The lat-
ter group included patients that received packed RBC
transfusions only. Of note, all the blood used in our in-
stitution is leukocyte-reduced. Patients who received
blood products other than RBCs were excluded to avoid
confounding effects of non-RBC transfusions. If a pa-
tient received both RBCs and another product such as
plasma, they were excluded as well. Patients were con-
sidered transfused if the transfusion occurred within
24 h prior to PICU admission, in order to capture all the
intra-operative and emergency room transfusions, as
well as during the PICU course. The time of the first
transfusion was designated as the “time of transfusion,”
but all RBC transfusions during the PICU course were
considered for the total volume.
Post-operative cardiovascular admission patients, as
well as patients that received extracorporeal support
(e.g., ECMO, chronic renal replacement therapy), were
excluded. In addition, the following patients were ex-
cluded due to low acuity: patients admitted to the PICU
solely for the purposes of procedural sedation and pa-
tients admitted for relatively minor illnesses but requir-
ing PICU status solely due to the need for continuation
of home ventilator support.
Data collected included age at admission, gender, vaso-
active agents used (y/n), reason for PICU admission
(e.g., respiratory, trauma, gastrointestinal, cardiovascular,
neurologic, oncologic), hemoglobin on admission <7 g/dL,
transfused (y/n), indications for transfusion (e.g., active
blood loss, hemodynamic instability, hypoxia, anemia,
unspecified), time of transfusion (defined as <0 h (prior
to PICU admission), 0 to <24 h, 24 to 48 h, >48 h), total
volume transfused (all RBC transfusions during the
PICU course), severity scores (PIM2, PRISM III, day 1
PELOD), PICU LOS (days), mechanical vent days, and
mortality (30-day, overall).
Patients on chronic ventilator support were considered
mechanically ventilated for the study if they needed
higher ventilator settings than used at home and were
classified as extubated when they got back to their base-
line ventilator settings. Patients brought into the PICU
intubated after a surgical procedure were not considered
to be on mechanical ventilation unless the duration of
support was >24 h.
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Organ dysfunction was defined according to the cri-
teria established by Wilkinson et al. [19] and subse-
quently modified by Proulx et al. [20]. Inotrope and
vasopressor use were combined together as done by
Gaies et al., who modified the original pressor scoring
system by Ceneviva et al. [21]. For the purposes of this
study, the use of both vasopressors and inotropes was
classified together as vasoactive agents [22].
The PRISM III score is based on clinical and labora-
tory parameters assessed during the first 12 h and the
PIM2 score on the first hour after admission to the
PICU [23, 24]. The PELOD score, which considers 12
variables relating to six organ dysfunctions (cardiovas-
cular, respiratory, hematological, neurological, hepatic,
renal dysfunction), is recorded daily for the entire
PICU admission or for the first 9 days of PICU stay,
whichever comes first [25].
Data were analyzed using IBM SPSS Statistics v. 21.0
(Armonk, NY). Significance for all analyses was assessed
at p < 0.05. Summary statistics was calculated for the
data. Quantitative data are expressed as the mean ± SD,
while nominal data are expressed as a percentage. Differ-
ences between the transfused and non-transfused
groups for quantitative variables were determined
using the t test, and nominal variables were compared
using the χ2 test. The ANOVA procedure, with post
hoc comparisons to investigate significant differences,
was used to analyze differences among the different time
points for time of first transfusion. These groups were de-
fined as <0 h (prior to PICU admission), 0 to <24 h, 24 to
48 h, and >48 h.
Multiple regression analyses were performed to exam-
ine predictors of decision to transfuse, PICU LOS, and
overall mortality. Dependent and independent variables
for each regression model are shown in Table 1.
Two additional sets of analyses were performed to
analyze the relationship between RBC transfusion and
mortality. The first was to look at the difference in
outcome measures between the transfused and non-
transfused patients by receiver operating characteristic
(ROC) curves using PRISM III, PIM2, and day 1
PELOD to predict mortality. The second analysis
involved a comparison of likelihood ratios between
the transfused and non-transfused groups. The cutoff
points for the analyses were obtained using a series
of logistic regression equations, with PRISM III
scores, PIM2 scores, or day 1 PELOD scores as the
independent variables, and mortality as the dependent
variable. Comparisons between the transfused and
non-transfused subjects for area under the curve
(AUC) and likelihood ratios were performed.
Results
Demographic and clinical data
There were 5185 admissions to our PICU during the
study period. Of these, 4975 met the inclusion criteria,
with 536 (10.8 %) admissions resulting in transfusions
for various indications. Demographic and clinical data
are shown in Table 2. The overall mortality rate was
90/4975 (1.8 %). Overall mortality and mortality within
30 days of admission were both significantly higher in
the transfused group. Non-transfused patients were
younger than transfused patients, while the male to fe-
male ratio was very similar between the two groups.
There were more patients with trauma, gastrointestinal,
and cardiovascular pathology as a reason for PICU admis-
sion among the transfused patients compared to non-
transfused. The PRISM III, PIM2, and day 1 PELOD
scores were significantly higher in the transfused group.
Variables indicating the level of support (use of vasoactive
agents, ventilator days, and PICU LOS) were all signifi-
cantly higher in the transfused group.
Timing of first transfusion
Comparisons between the time points of first transfusion
groups are shown in Table 3. The majority of transfu-
sions (45 %) occurred within 0–<24 h following PICU
admission, while 13 % occurred prior to PICU admis-
sion. The patients transfused prior to PICU admission
were significantly older than those transfused at the
other time points. The PRISM III and PIM2 scores were
significantly lower in patients transfused prior to PICU
admission compared to the other time intervals. All
other time periods had comparable severity scores.
Table 1 Dependent and independent variables for each regression model
Dependent variable Independent variables
Transfusion (y/n) Hemoglobin concentration <7 g/dL, PIM2, PRISM III, day 1 PELOD, reason for PICU admission
PICU LOS (days)a Age at admission, gender, transfusion, vasoactive agents, PIM2, PRISM III, day 1 PELOD, reason for PICU admission
Mortality (y/n) Age at admissionc, gender, volume transfused (mL/kg), hemoglobin concentration, PIM2 score, PRISM III score, vasoactive
agents, PIM2, PRISM III, day 1 PELOD, reason for PICU admission
Mortality (y/n)b Age at admissionc, gender, time of transfusion, vasoactive agents, PIM2, PRISM III, day 1 PELOD, reason for PICU admission
PICU pediatric intensive care unit, LOS length of stay
aDue to non-normality of data, the natural log of PICU LOS was used
bTransfused patients only
cAges were divided by 10 prior to analysis for ease of interpretation of the odds ratio
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Among the patients being transfused prior to PICU
admission, 90 % were admitted for post-operative or
trauma reasons. Overall and 30-day mortality were
lowest for patients being transfused prior to PICU ad-
mission. Patients transfused at the 24–48 h time
interval had the highest overall and 30-day mortality
of the four groups.
Decision to transfuse
The results of the regression procedure examining deci-
sion to transfuse are shown in Table 4. A serum
hemoglobin <7 g/dL increased the chances of transfu-
sion 50-fold. Independent of serum hemoglobin, for
every 10-point increase in initial PRISM III scores, there
was a 1.4-fold increase in the chance of RBC transfusion.
Cardiovascular and trauma patients were more likely to
be transfused than those with a respiratory diagnosis,
while patients with a neurologic diagnosis were less
likely to be transfused than patients with a respiratory
diagnosis. PIM2 and day 1 PELOD scores were not asso-
ciated with transfusion.
PICU LOS
Several independent variables were predictive of longer
PICU LOS (Table 5). Transfusion was associated with a
2.3-day increase in PICU LOS, while the use of
vasoactive agents was associated with a 1.5-day increase
in PICU LOS. Cardiovascular, neurologic, and trauma
reasons for PICU admission were all associated with sig-
nificantly shorter PICU LOS compared to patients ad-
mitted for respiratory reasons. Gender and age were not
significant predictors of PICU LOS.
Factors related to mortality
PRISM III and PIM2 scores and the use of vasoactive
agents and RBC volume transfused were associated with
mortality (Table 6). Serum hemoglobin levels were not
significantly predictive in the model. Trauma patients
were 4.4 times more likely to die, relative to the refer-
ence diagnosis, respiratory.
Timing of transfusion related to mortality
The results for the regression analysis examining mortal-
ity in the transfused group only are shown in Table 7.
Although the overall effect of timing of transfusion was
significant, only the 0- to <24-h group was different
from the reference group (24–48 h), with a significantly
decreased risk of mortality. Age at admission, vasoactive
agents, PIM2, PRISM III, and day 1 PELOD scores were
also significantly predictive of mortality. Cardiovascular
patients were also associated with a significantly lower
mortality, relative to the reference diagnosis, respiratory.
Table 2 Demographic and clinical data of the study sample
Variables Non-transfused# Transfused^ p value
Age at admission (months) 83.2 ± 74.6 92.4 ± 81.2 0.01
Sex (M/F) 2385/2054 289/247 0.98
Hemoglobin (g/dL) 12.0 ± 2.2 10.4 ± 2.4 <0.001
Reason for PICU admission
Respiratory 1687/4439 (38 %) 95/536 (17.7 %) <0.001
Cardiovascular 160/4439 (3.6 %) 70/536 (13.1 %) <0.001
Gastrointestinal 134/4439 (3.0 %) 35/536 (6.5 %) <0.001
Neurologic 703/4439 (15.8 %) 37/536 (6.9 %) <0.001
Oncologic 160/4439 (3.6 %) 28/536 (5.2 %) <0.06
Trauma 429/4439 (9.7 %) 106/536 (19.8 %) <0.001
PRISM III score 2.5 ± 4.1 7.7 ± 9.0 <0.001
PIM2 score −5.1 ± 1.5 −4.1 ± 1.8 <0.001
Day 1 PELOD 5.3 ± 5.2 9.7 ± 9.2 <0.001
Vasoactive agents 408/4439 (9.2 %) 94/536 (17.5 %) <0.001
PICU LOS (days) 3.1 ± 5.9 9.5 ± 14.7 <0.001
Mechanical ventilation (days) 3.9 ± 8.9 9.1 ± 14.6 <0.001
Mortality n (%) 42/4439 (0.9 %) 48/536 (9.0 %) <0.001
30-day mortality n (%) 40/4439 (0.9 %) 44/536 (8.2 %) <0.001
PICU pediatric intensive care unit, LOS length of stay
#n = 4439 for age at admission, PIM2, day 1 PELOD, PICU LOS; n = 1697 for hemoglobin level on admission; n = 4437 for PRISM III; n = 1131 for
mechanical ventilation
^n = 530 for age at admission and PIM2; n = 440 1697 for hemoglobin level on admission; n = 529 for PRISMIII; n = 536 for day 1 PELOD; n = 406 for PICU LOS; n = 304
for for mechanical ventilation
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Table 3 Patient characteristics by timing of transfusion relative to PICU admission
Timing of first transfusion <0 h^ 0 to <24 h@ 24–48 h$ >48 h& p value
Age at admission (months) 128 ± 74 91 ± 80 86 ± 87 80 ± 81 0.001*
Gender (females) 40 (56 %) 116 (48 %) 28 (37 %) 57 (40 %) 0.065
Indications for PRBC
Active blood loss 5 (7 %) 81 (34 %) 29 (38 %) 32 (22 %) <0.001
Hemodynamic instability 3 (4 %) 63 (26 %) 15 (20 %) 35 (24 %) 0.001
Hypoxia 0 (0 %) 9 (4 %) 3 (4 %) 11 (8 %) 0.053
Anemia 1 (1 %) 71 (30 %) 16 (21 %) 49 (34 %) <0.001
Unspecifieda 62 (87 %) 1 (0.4 %) 5 (7 %) 2 (1 %) <0.001
Reason for PICU admission
Cardiovascular 3 (4 %) 30 (13 %) 14 (18 %) 22 (15 %) 0.056
Post-operative 40 (56 %) 35 (15 %) 10 (13 %) 16 (11 %) <0.001
Respiratory 1 (1 %) 39 (16 %) 18 (24 %) 37 (26 %) <0.001
Trauma 24 (34 %) 44 (18 %) 16 (21 %) 21 (15 %) 0.009
Oncologic 0 (0 %) 21 (9 %) 1 (1 %) 5 (4 %) 0.003
Severity scores
PRISM III score 3.7 ± 5.2 9.2 ± 10.3 8.0 ± 7.9 7.4 ± 8.1 <0.001*
PIM2 score −5.1 ± 1.6 −4.0 ± 1.9 −3.8 ± 1.8 −4.0 ± 1.7 <0.001*
Day 1 PELOD 9.2 ± 7.2 14.2 ± 12 13.1 ± 11.9 12.6 ± 10.2 0.006*
Hemoglobin (g/dL) 9.1 ± 2.0 7.5 ± 2.1 8.2 ± 3.3 7.9 ± 1.4 <0.001**
Transfused amount (mL/kg) 12.4 ± 6.6 13.3 ± 7.3 13.1 ± 5.8 13.5 ± 5.5 0.679
Mortality 1/71 (1 %) 21/240 (9 %) 13/76 (17 %) 13/142 (9 %) 0.012
30-day mortality 1/71 (1 %) 21/240 (9 %) 12/76 (16 %) 10/142 (7 %) 0.016
PRBC packed red blood cells; PICU pediatric intensive care unit
^n = 71 with the following exception: n = 49 for pre-transfusion Hb
@n = 240 with the following exceptions: n = 239 for age at admission, PIM2, pre-transfusion Hb, and transfused amount; n = 238 for PRISM III
$n = 76 with the following exceptions: n = 74 for PRISM III and PIM2
&n = 143 with the following exceptions: n = 140 for age at admission, PRISM III, and PIM2; n = 142 for day 1 PELOD and transfused amount; n = 139 for
pre-transfusion hb
*<0 h group significantly different from all other groups, p < 0.01 (all other groups not significantly different from one another, p > 0.05)
**<0 h group significantly different from 0–<24 h group and >48 h group, p < 0.03
aPatients that had no reason identified for transfusion
Table 4 Logistic regression analysis, with transfusion as the dependent variable (n = 2207)
Variable Odds ratio 95 % confidence interval p value
PRISM III score 1.04 1.01–1.07 0.006
Hemoglobin ≥7 g/dL 0.02 0.01–0.03 <0.001
Reason for PICU admissiona
Cardiovascular 2.26 1.39–3.66 0.001
Neurologic 0.58 0.35–0.96 0.034
Trauma 2.41 1.66–3.50 <0.001
Otherb 1.32 0.96–1.83 0.093
Day 1 PELOD 1.02 0.997–1.04 0.106
PIM2 score 1.09 0.99–1.19 0.084
aReason for PICU admission, odds ratio relative to respiratory (reference group)
bOther includes all other categories (e.g., endocrinologic, gastrointestinal, infectious, oncologic)
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AUC and likelihood ratios
Transfusion did not significantly modify the discrimin-
atory performance (ability to predict mortality) of the
three severity scores (Table 7). However, the positive
likelihood ratios (LR+) calculated for all three scores for
the non-transfused patients were all significantly higher
than the LR+ for the transfused patients. The differences
ranged from sixfold higher for day 1 PELOD scores to
over tenfold higher for PIM2 scores. There were no
significant differences found between transfused and
non-transfused patients for negative likelihood ratios
(LR−) for any of the three scores.
Discussion
The goal of this study was to test the hypothesis that trans-
fusion is an independent predictor of mortality and that this
relationship is independent of severity of illness. Our data
showed that increases in transfusion volume, PRISM III
score, and PIM2 score, as well as use of vasoactive agents,
were significantly predictive of mortality. Additionally, the
LR+ calculated for all three scores indicated a significant
difference between the transfused and the non-transfused
patients. Based upon these data, one could hypothesize
that the predictive ability of all three severity scores
could be improved by accounting for transfusion status.
Table 5 Multiple regression analyses, with PICU LOS as the dependent variable (n = 4832)
Variables β-coefficient 95 % confidence interval p value
Dependent variable: ln(PICU LOS)a
PIM2 score 0.138 0.118–0.159 <0.001
Transfusion 0.833 0.731–0.935 <0.001
Vasoactive agents 0.377 0.302–0.452 <0.001
Day 1 PELOD 0.013 0.008–0.018 <0.001
PRISM III score −0.011 −0.018 to −0.003 0.017
Reason for PICU admissionb
Cardiovascular −0.308 −0.447 to −0.170 <0.001
Neurologic −0.239 −0.322 to −0.156 <0.001
Trauma −0.441 −0.538 to −0.343 <0.001
Otherc −0.262 −0.330 to −0.195 <0.001
Gender −0.027 −0.080 to −0.026 0.324
Age at admission (months) 0.000 0.000 to −0.000 0.716
aDue to the non-normality of the variable PICU LOS, the variable was transformed by taking its natural logarithm prior to analysis; the β-coefficients are interpreted
by calculating the antilog, which for transfusion is e0.833, meaning that transfused subjects had a 2.3 day longer PICU LOS than non-transfused subjects
bReason for PICU admission, odds ratio relative to respiratory (reference group)
cOther includes all other categories (e.g., endocrinologic, gastrointestinal, infectious, oncologic)
Table 6 Logistic regression analyses, with mortality as the dependent variable (n = 2208)
Variable Odds ratio 95 % confidence interval p value
PIM2 score 1.69 1.35–2.12 <0.001
PRISM III score 1.19 1.14–1.25 <0.001
Volume transfused (mL/kg) 1.08 1.03–1.13 0.001
Inotropes 2.99 1.40–6.41 0.005
Age at admission (months)a 0.96 0.92–1.01 0.144
Hemoglobin (g/dL) 1.07 0.93–1.22 0.366
Gender 1.64 0.81–3.31 0.170
Reason for PICU admissionb
Cardiovascular 2.45 0.80–7.53 0.117
Neurologic 0.96 0.28–3.32 0.948
Trauma 4.39 1.22–15.85 0.024
Otherc 1.90 0.53–6.77 0.324
aAll ages divided by 10 prior to analysis
bReason for PICU admission, odds ratio relative to respiratory (reference group)
cOther includes all other categories (e.g., endocrinologic, gastrointestinal, infectious, oncologic)
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As expected, low serum hemoglobin (<7 g/dL) mark-
edly and significantly increased the odds of a transfusion.
Despite this strong relationship, hemoglobin concentra-
tion was not a significant predictor of mortality. It is
often the sicker patient that needs a transfusion, which
is supported by our findings that a higher PRISM III
score was independently associated with transfusion.
But this creates a dilemma as univariate analyses dem-
onstrated numerous differences between the transfused
and non-transfused cohort. Regression modeling was
used to control for those differences so that we could
examine transfusion as an independent risk factor for
mortality.
Both AUC and likelihood ratios were used to examine
the potential for RBC transfusions to modify the predict-
ive ability of severity scoring systems (Table 8). Whereas
AUCs are derived from a large number of decision
points [26], likelihood ratios use an optimally derived
cut-point to express the change in the risk that a disease
process is present at a given measurement and has been
previously used to examine the predictive capability of
severity scores [27–30]. The likelihood ratio for both
transfused and not transfused patients should be similar
if transfusion is merely an indication of severity. What
we found instead was, although severity scores predict
mortality rather well (LR+ values >10) for both groups,
there was a statistically significant difference in the posi-
tive likelihood ratios. This suggests that transfusions
introduce a degree of unpredictability by exhibiting sig-
nificantly lower LR+. The LR+ tells us how much to
increase the probability of mortality if the test is posi-
tive. The inference is severity scores predict mortality
better in the non-transfused group. The significant
difference in LR+ and the strength of transfusion as
an independent risk factor in regression modeling
lead us to believe that transfusion adds risk independ-
ent of disease severity.
If RBC transfusions by themselves are independent
predictors of mortality as suggested by our study, one
could propose that existing severity scores should be
Table 7 Logistic regression analyses with only transfused subjects, with mortality as the dependent variable (n = 514)
Variable Odds ratio 95 % confidence interval p value
PIM2 score 1.59 1.10–2.28 0.013
PRISM III score 1.17 1.07–1.28 0.001
Agea 0.90 0.82–0.98 0.016
Transfusionb
<0 h 0.06 0.002–2.00 0.118
0 h to <24 h 0.08 0.02–0.32 <0.001
>48 h 0.36 0.10–1.33 0.124
Gender 2.80 0.95–8.25 0.062
Vasoactive agents 4.94 1.37–17.86 0.015
Day 1 PELOD score 1.06 0.99–1.13 0.117
Reason for PICU admissionc
Cardiovascular 0.14 0.03–0.66 0.013
Neurologic 2.37 0.41–13.78 0.338
Trauma 0.81 0.12–5.42 0.830
Otherd 1.27 0.27–5.90 0.759
aAll ages divided by 10 prior to analysis
bRefers to timing of transfusion relative to ICU admission; <0 h group was transfused prior to ICU admission; the reference group was transfused within the 24–
48 h time frame
cReason for PICU admission, odds ratio relative to respiratory (reference group)
dOther includes all other categories (e.g., endocrinologic, gastrointestinal, infectious, oncologic)
Table 8 AUC and likelihood ratios in the prediction of mortality
Severity Score Non-transfused Transfused p value
AUC AUC
PRISM III 0.91 (0.84–0.97) 0.89 (0.83–0.95) 0.74
PIM2 0.93 (0.89–0.97) 0.88 (0.82–0.94) 0.19
Day 1 PELOD 0.92 (0.86–0.98) 0.90 (0.84–0.95) 0.61
LR+ (95 % CI) LR+ (95 % CI)
PRISM III 471 (166–1332) 64 (23–176) 0.007
PIM2 471 (167–1333) 38 (15–97) 0.0004
Day 1 PELOD 314 (120–825) 53 (18–143) 0.01
LR− (95 % CI) LR− (95 % CI)
PRISM III 0.57 (0.44–0.74) 0.39 (0.25–0.59) 0.12
PIM2 0.57 (0.44–0.74) 0.55 (0.41–0.74) 0.84
Day 1 PELOD 0.64 (0.51–0.81) 0.52 (0.38–0.72) 0.28
AUC area under the curve from a receiver operating characteristic (ROC)
analysis; LR+ positive likelihood ratio, LR− negative likelihood ratio; CI
confidence interval
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modified to account for transfusion status. With this in
mind, we examined if any relationship existed between
the timing of transfusions and mortality. This timing is
critical, as the relationship of transfusion with mortality
would have to be shown to occur early enough in the
course of illness to be available for inclusion into the
scoring of disease severity. Our data indicate, however,
that the groups with most mortality are those that have
transfusions later in their course (24–48 h). One possible
explanation for the worse mortality in patients who re-
ceive their first transfusion later could be that, at least in
adults, it has been shown that organ failure which oc-
curs early in the ICU course and therapies early in that
first 48 h could influence the patient’s recovery [31].
One could speculate that this is likely a vulnerable
period during which time patients are precariously
poised to either improve or deteriorate. One could
hypothesize that patients transfused early in their PICU
course do better because there is less likelihood for an
established inflammatory process and the capacity for
transfusion to have a negative impact on mortality is
diminished.
Limitations
Both the Virtual PICU Systems database and our trans-
fusion database contain prospectively maintained data,
but the study hypothesis was conceived only after the in-
formation was collected. The single center retrospective
design limits our ability to account for the way transfu-
sion was applied to critically ill patients. Another limita-
tion is that, severity scores such as PIM2 and PRISM III
were not designed to examine therapeutic interventions
that most often occur after the first day of ICU admis-
sion. Thus, at best, severity scores remain surrogates for
acuity and are incomplete depictions of true severity.
We excluded certain high mortality groups such as pa-
tients receiving extracorporeal support with ECMO and
chronic renal replacement therapy because these pa-
tients often received other blood products. In addition,
the decision to transfuse in these patients is not one that
is clinically based but rather protocol driven.
Conclusions
We showed RBC transfusion to be an important risk
factor that is statistically independent of severity in
critically ill patients. The transfusions that seem to
associate most with mortality happen after that first
24–48 h. Currently, severity scores do not account
for RBC transfusions but the predictive ability of se-
verity scores could perhaps be improved by account-
ing for them. However, this remains outside of the
timing of data collection for most severity scores ex-
cept for PELOD scores.
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